Weikang Bio-Technology Group Co., Inc. Retains Elite IR as Investor Relations Counsel to Expand Investor Awareness

HARBIN, CHINA--(Marketwire - May 12, 2010) - Weikang Bio-Technology Group Co., Inc. (OTCBB: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that it has retained Elite Investor Relations to increase its investor awareness.

"We are very excited to work with Elite IR as we launch a new investor relations campaign to raise our profile and ensure that the broad investment community fully understands our growth prospects," commented Mr. Ying Wang, Chairman & CEO of Weikang Bio-Technology Group. "During our year which ended December 31, 2009, our Company recorded revenue of $47.48 million, compared to $12.85 million for 2008, an increase of $34.63 million or 269% and earnings of $0.62 per share These results demonstrate that Weikang Bio-Technology's approach as a vertically integrated developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), prescription pharmaceuticals and other health and nutritional products gives us many operational advantages to capitalize on the rapidly growing demand for medicines and health supplements in China."

"We are looking forward to working with Weikang Bio-Technology Group in developing and executing a highly visible investor relations campaign," commented Ms. Nancy Chen, Managing Partner of Elite IR. "Our goals are to improve visibility and sponsorship throughout the global financial communities, creating a more appropriate market valuation and understanding of the potential of Weikang Bio-Technology Group."

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com.

About Elite IR

Elite IR is a professional investor relations service provider focused on offering the highest level of personalized IR support to U.S. and Hong Kong listed companies. The Company provides high quality, strategic, service-oriented IR counsel that is critical to maintaining visibility in the global equity markets and a fair market value. As a full service firm, Elite IR is committed to building a long-term cooperation with its clients. Additional information can be found at http://www.elite-ir.com.

Safe Harbor Safe Harbor

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our S-1 dated March 25, 2010, our 10-K for the year ended December 31, 2009, filed on March 31, 2010 and other recent filings. These filings are available at http://www.sec.gov/. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.